Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Zymeworks Inc.

Zymeworks Inc. (ZYME) Stock Overview

Explore Zymeworks Inc.’s financial performance, market position, analyst ratings, and future outlook.

ZYME●NASDAQ
HealthcareBiotechnology
$27.12
$0.60(2.26%)
U.S. Market opens in NaNh NaNm

Zymeworks Inc. (ZYME)

Meyka AI Score

Z

Key Financials

Market Cap2B
P/E Ratio-13.60
EPS (TTM)$-2.02
ROE-0.72%
Fundamental Analysis

AI Price Forecasts

1 Month$27.74
3 Months$36.30
1 Year Target$33.50

ZYME Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Zymeworks Inc. (NASDAQ: ZYME) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Zymeworks Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ZYME on the NASDAQ shows an RSI of 51.12, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $33.50 for the NASDAQ listing.

Key metrics behind Zymeworks Inc.'s NASDAQ-traded stock include a P/E ratio of -13.60 and a market capitalization of 2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ZYME on the NASDAQ.

Price Performance (NASDAQ: ZYME)

1-Day Change
2.26%
5-Day Change
-1.56%
1-Month Change
-4.07%
3-Month Change
12.30%
6-Month Change
12.16%
Year-to-Date (YTD) Change
3.000%
1-Year Change
57.40%
3-Year Change
333.92%
5-Year Change
-8.69%
All-Time (Max) Change
108.62%

Contact Information

https://www.zymeworks.com
16046781388
108 Patriot Drive, Middletown, DE, 19709

Company Facts

2,310 Employees
IPO DateApr 28, 2017
CountryUS
Actively Trading

Frequently Asked Questions